OKYO Pharma Limited develops investigational ophthalmic therapies for neuropathic corneal pain and inflammatory eye diseases. The company’s lead candidate, urcosimod, formerly OK-101, is described as a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, with development centered on ocular pain and inflammation.
Recurring company updates cover urcosimod clinical data, patient-reported outcomes from a completed Phase 2 study in neuropathic corneal pain, FDA IND and Fast Track status for the NCP program, scientific advisory and ophthalmology-conference presentations, ordinary-share ownership disclosures, and purchases of Nasdaq-listed ordinary shares by company insiders.
OKYO Pharma (OKYO) enrolled the first patients in its Phase 3 NEPTUNE trial evaluating urcosimod for neuropathic corneal pain.
Dr. Melissa Toyos enrolled the first patients at Toyos Clinic in Nashville, Tennessee. The study has initiated in the United States, with enrollment planned at multiple sites across the United States and Europe, including Italy, Spain and France. Patients will receive 4 drops per day for 12 weeks.
The primary efficacy endpoint is the change in ocular pain from baseline to the end of treatment, measured using a visual analogue scale (VAS). Additional endpoints include quality-of-life scores and findings from in-vivo confocal microscopy, an eye-imaging technique. NEPTUNE is designed as a registrational study in accordance with FDA guidance. Neuropathic corneal pain currently has no FDA-approved treatment options.
OKYO Pharma (OKYO) will present at Eyecelerator on October 8, 2026, and participate in two other ophthalmic conferences.
CEO Robert J. Dempsey will speak about corneal and anterior segment diseases at Eyecelerator in New Orleans. OKYO’s leadership will also attend the American Academy of Optometry meeting in Anaheim, September 30–October 1, and the American Academy of Ophthalmology meeting in New Orleans, October 9–12.
OKYO Pharma (OKYO) will present at the Ophthalmology Futures European Forum on September 10 and ESCRS iNovation Day on September 11, 2026, in London.
The company aims to engage clinicians, industry leaders, and investors as it advances urcosimod, its lead asset for neuropathic corneal pain (NCP), through its global Phase 3 pivotal NEPTUNE trial. OKYO reports recent positive feedback from a U.S. FDA Type D meeting, which it says validated the regulatory and clinical path forward for urcosimod, and notes an Annual Report filing reflecting a strengthened cash position. OKYO plans to initiate a global Phase 3 pivotal trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
OKYO Pharma (OKYO) will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 10, 2026, at 8:35 AM ET, featuring Chief Medical Officer Flavio Mantelli and Chief Development Officer Gary Jacob, moderated by Cantor Fitzgerald’s Eric Fitzgerald.
The company will also be available for one-on-one meetings during the event. OKYO links this participation to recent positive FDA Type D meeting feedback that validated the regulatory and clinical path for its NCP candidate urcosimod, a strengthened cash position disclosed in its latest Annual Report, and plans to start a global Phase 3 pivotal trial in the second half of the year with about 111 patients on a single-dose regimen.
OKYO Pharma (Nasdaq: OKYO) reported that Chief Scientific Officer Raj Patil, PhD, has increased his personal stake in the company by purchasing 3,363 ordinary shares on Nasdaq at $1.49 per share, bringing his total holding to 20,030 ordinary shares.
OKYO Pharma is a clinical-stage biopharmaceutical company developing investigational therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. According to the company, it plans to initiate a global Phase 3 pivotal trial in the second half of this year, enrolling about 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
OKYO Pharma (Nasdaq: OKYO) will participate in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026. Company representatives will include CEO Robert J. Dempsey, CFO Keeren Shah, and CMO Flavio Mantelli.
The company is a clinical-stage biopharmaceutical developer of therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases. According to OKYO Pharma, it plans to initiate a global Phase 3 pivotal trial in the second half of this year, enrolling about 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
The conference will feature virtual 1:1 meetings, which can be scheduled through a BTIG representative. Additional corporate and contact information is available on OKYO Pharma’s website and through its business development and investor relations contact.
OKYO Pharma (Nasdaq: OKYO) reported that Non-Executive Director John Brancaccio purchased 5,000 ordinary shares on Nasdaq at $1.48 per share, increasing his total holding to 35,201 shares. The company is a clinical-stage biopharmaceutical developer of investigational therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases, with its ordinary shares listed on the Nasdaq Capital Market.
According to OKYO Pharma, the company plans to initiate a global Phase 3 pivotal clinical trial of urcosimod for NCP in the second half of this year, targeting enrollment of approximately 111 patients to assess a single-dose regimen.
OKYO Pharma (Nasdaq: OKYO), a clinical-stage biopharmaceutical company focused on neuropathic corneal pain (NCP) and anterior segment eye diseases, announced that Chief Executive Officer Robert J. Dempsey purchased 15,000 ordinary shares of the company on Nasdaq at $1.54 per share.
OKYO’s ordinary shares trade on the Nasdaq Capital Market. According to OKYO Pharma, the company plans to initiate a global Phase 3 pivotal clinical trial of urcosimod for NCP in the second half of this year, targeting enrollment of approximately 111 patients in a single-dose regimen study.
OKYO Pharma (Nasdaq: OKYO) reported that Chief Development Officer and Director Gary S. Jacob, PhD, purchased 3,500 ordinary shares on Nasdaq at $1.40 per share, increasing his total holding to 112,420 ordinary shares.
The company is a clinical-stage biopharmaceutical developer of therapies for neuropathic corneal pain (NCP) and anterior segment eye diseases and plans to start a global Phase 3 pivotal trial in the second half of this year, enrolling about 111 patients to evaluate a single-dose regimen of urcosimod for NCP.
OKYO Pharma (Nasdaq: OKYO) reported that its Chief Medical Officer, Flavio Mantelli, MD, PhD, purchased 20,000 ordinary shares of the company on Nasdaq at $1.40 per share. OKYO is a clinical-stage biopharmaceutical company focused on neuropathic corneal pain (NCP) and anterior segment eye diseases, with its ordinary shares traded on the Nasdaq Capital Market.
According to OKYO Pharma, the company plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.